Godavari Biorefineries Inc Forms New Subsidiary in USA

Godavari Biorefineries Ltd has informed the BSE about the incorporation of a new wholly owned subsidiary in the USA. The step-down subsidiary, Godavari Biorefineries Inc, has established Sathgen Therapeutics, LLC under US law on November 17, 2025. This new entity will function as a wholly owned step-down subsidiary of Godavari Biorefineries Ltd.

The incorporation involves a share capital of USD 350,000, which has been subscribed by Godavari Biorefineries Inc. The transaction was completed through cash consideration. Sathgen Therapeutics, LLC will engage in pharmaceutical marketing, focusing on business development for drugs developed by Godavari Biorefineries Ltd in India.

The incorporation does not fall within related party transactions, and there is no interest from the promoter or promoter group in the newly formed entity. No governmental or regulatory approvals were required for this incorporation. The transaction was executed at arm’s length, ensuring compliance with relevant regulations.

As a wholly owned step-down subsidiary, Sathgen Therapeutics, LLC will operate in the pharmaceutical marketing sector. The entity will not have a turnover history for the past three years, as it was recently incorporated. The company will be based in the USA, expanding the geographical presence of Godavari Biorefineries Ltd.

Godavari Biorefineries Ltd is focused on expanding its operations in the pharmaceutical sector. The company is involved in the development and marketing of various chemical and bio-based products. The incorporation of Sathgen Therapeutics, LLC aligns with its strategy to enhance its business development capabilities in international markets.